Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbuster ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management ... with three of Lilly's insulin products, including Humalog and Lyumjev ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and differentiate its products to stay ahead of the competition.

Eli Lilly and Company ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

Competitors are developing their own innovative treatments, which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and ...